Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. uri icon

Overview

abstract

  • There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.

publication date

  • July 28, 2020

Research

keywords

  • Adrenal Cortex Hormones
  • Antiviral Agents
  • COVID-19
  • COVID-19 Drug Treatment
  • Hematopoietic Stem Cell Transplantation
  • Immunologic Factors
  • Neoplasms

Identity

PubMed Central ID

  • PMC7386267

Scopus Document Identifier

  • 85089457585

Digital Object Identifier (DOI)

  • 10.1136/annrheumdis-2020-217706

PubMed ID

  • 32736007

Additional Document Info

volume

  • 26

issue

  • 11